876 related articles for article (PubMed ID: 34064039)
1. The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy.
Kouhpayeh S; Shariati L; Boshtam M; Rahimmanesh I; Mirian M; Esmaeili Y; Najaflu M; Khanahmad N; Zeinalian M; Trovato M; Tay FR; Khanahmad H; Makvandi P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34064039
[TBL] [Abstract][Full Text] [Related]
2. Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors.
Brosey CA; Houl JH; Katsonis P; Balapiti-Modarage LPF; Bommagani S; Arvai A; Moiani D; Bacolla A; Link T; Warden LS; Lichtarge O; Jones DE; Ahmed Z; Tainer JA
Prog Biophys Mol Biol; 2021 Aug; 163():171-186. PubMed ID: 33636189
[TBL] [Abstract][Full Text] [Related]
3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
4. The Poly(ADP-ribose) polymerase PARP-1 is required for oxidative stress-induced TRPM2 activation in lymphocytes.
Buelow B; Song Y; Scharenberg AM
J Biol Chem; 2008 Sep; 283(36):24571-83. PubMed ID: 18599483
[TBL] [Abstract][Full Text] [Related]
5. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose)glycohydrolase is an upstream regulator of Ca2+ fluxes in oxidative cell death.
Blenn C; Wyrsch P; Bader J; Bollhalder M; Althaus FR
Cell Mol Life Sci; 2011 Apr; 68(8):1455-66. PubMed ID: 20878536
[TBL] [Abstract][Full Text] [Related]
7. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
8. Potential Roles of the Renin-Angiotensin System in the Pathogenesis and Treatment of COVID-19.
Lu L; Liu X; Jin R; Guan R; Lin R; Qu Z
Biomed Res Int; 2020; 2020():7520746. PubMed ID: 33204713
[TBL] [Abstract][Full Text] [Related]
9. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.
Peng MY; Liu WC; Zheng JQ; Lu CL; Hou YC; Zheng CM; Song JY; Lu KC; Chao YC
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065735
[TBL] [Abstract][Full Text] [Related]
10. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y
Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119
[TBL] [Abstract][Full Text] [Related]
11. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
Rohilla S
Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
[TBL] [Abstract][Full Text] [Related]
12. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
Front Immunol; 2021; 12():749291. PubMed ID: 34867978
[TBL] [Abstract][Full Text] [Related]
13. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19.
Kumar R; Rathi H; Haq A; Wimalawansa SJ; Sharma A
Virus Res; 2021 Jan; 292():198235. PubMed ID: 33232783
[TBL] [Abstract][Full Text] [Related]
14. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
[TBL] [Abstract][Full Text] [Related]
15. The fight against COVID-19: Striking a balance in the renin-angiotensin system.
Dean AQ; Bozza WP; Twomey JD; Luo S; Nalli A; Zhang B
Drug Discov Today; 2021 Oct; 26(10):2214-2220. PubMed ID: 33865979
[TBL] [Abstract][Full Text] [Related]
16. Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis.
Rajawat J; Chandra A
Curr Drug Targets; 2021; 22(13):1477-1484. PubMed ID: 33494667
[TBL] [Abstract][Full Text] [Related]
17. Microglial NMDA receptors drive pro-inflammatory responses via PARP-1/TRMP2 signaling.
Raghunatha P; Vosoughi A; Kauppinen TM; Jackson MF
Glia; 2020 Jul; 68(7):1421-1434. PubMed ID: 32036619
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
19. Drugs acting on the renin-angiotensin system and SARS-CoV-2.
Vitiello A; Pelliccia C; Ferrara F
Drug Discov Today; 2021 Apr; 26(4):870-874. PubMed ID: 33486116
[TBL] [Abstract][Full Text] [Related]
20. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.
Milewska A; Chi Y; Szczepanski A; Barreto-Duran E; Dabrowska A; Botwina P; Obloza M; Liu K; Liu D; Guo X; Ge Y; Li J; Cui L; Ochman M; Urlik M; Rodziewicz-Motowidlo S; Zhu F; Szczubialka K; Nowakowska M; Pyrc K
J Virol; 2021 Jan; 95(4):. PubMed ID: 33219167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
